Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...

(RTTNews) - Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy ...

Q32 Bio (NASDAQ:QTTB – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th.Analysts expect Q32 Bio to post earnings of ($1.25) per share ...

Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today ...

Piper Sandler downgraded Q32 Bio (QTTB) to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company’s decision to discontinue complement inhibitor ...

Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata, AA, at the 2025 American Academy of Dermatology ...

QTTB stock opened at $2.88 on Tuesday. Q32 Bio has a 12-month low of $2.60 and a 12-month high of $53.79. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio ...